Categories: Health

Pfizer to explore pneumococcal jab with third booster of Covid vaccine

<p>
<strong>Pfizer on Monday announced a study to explore coadministration of its pneumococcal vaccine along with a third dose of the Pfizer-BioNTech Covid-19 vaccine in older adults.<br />
</strong><br />
Pfizer, in a statement, announced that "the first enrolled subjects have received their immunisations as part of a new study in adults ages 65 or older exploring the coadministration of the company's 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech Covid-19 vaccine, currently authorised by the Food and Drug Administration (FDA) under an emergency use authorisation (EUA)".<br />
<br />
The trial aims to describe safety when both vaccines are co-administered, with follow-up six months after vaccination and to describe immune responses produced by each of the vaccines.<br />
<br />
The trial will include 600 adults who will be recruited from the pivotal Phase 3 Pfizer-BioNTech Covid-19 vaccine trial and will have received their second dose of the vaccine at least six months prior to entering the coadministration study.<br />
<br />
The participants will be randomised to one of three groups: 20vPnC plus Pfizer-BioNTech Covid-19 vaccine booster; 20vPnC plus placebo; and Pfizer-BioNTech Covid-19 vaccine booster plus placebo.<br />
<br />
Boosters and new versions of vaccines that target the Covid variants are already being explored by both Pfizer and Moderna.<br />
<br />
Pfizer CEO Albert Bourla had announced that Covid vaccine recipients will "likely" need a third dose between six to 12 months after they're fully vaccinated. The company is now testing a third booster shot of its vaccine on fully vaccinated people.<br />
<br />
US pharmaceutical Moderna in its Phase 2 study found that a third booster shot of its Covid vaccine can rapidly increase the level of antibodies in previously inoculated people.<br />
<br />
The 20vPnC candidate vaccine is in development for the prevention of invasive disease and pneumonia caused by 20 serotypes of Streptococcus pneumoniae in the vaccine in adults ages 18 years and older.</p>

IANS

Recent Posts

“India will not hesitate to use every method to root out terrorism,” says Rajnath Singh

Defence Minister Rajnath Singh, addressing officers and sailors onboard India's first indigenous aircraft carrier INS…

3 minutes ago

Tibetan leaders urge global action at Tokyo convention, highlight China’s rights abuses in Tibet

The leadership team from the Central Tibetan Administration (CTA) arrived in Tokyo to participate in…

1 hour ago

“Day is not far when Maoist violence will be completely eradicated”: PM Modi

Hailing the centre's fight against naxalism and red terror, Prime Minister Narendra Modi said that…

3 hours ago

If Navy had acted in Operation Sindoor, Pakistan could have split into four parts: Rajnath Singh aboard INS Vikrant

Defence Minister Rajnath Singh aboard India's first indigenously built aircraft carrier, INS Vikrant, on Friday…

3 hours ago

Delhi Police arrests 38 Bangladeshis who moved from Nuh to Delhi via Bihar

In a coordinated operation, the North West District of Delhi Police apprehended 38 Bangladeshi nationals…

4 hours ago

Tibet Action Institute alleges China’s boarding schools erasing Tibetan identity, culture

A recent report by the Tibet Action Institute has unveiled troubling evidence of mistreatment, forced…

4 hours ago